Brandes Investment Partners’s AstraZeneca AZN Stock Holding History

Brandes Investment Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-120,599	Closed	-$8.17M	–	162
2017 Q3	$8.17M	Buy	120,599 +4,805	+4%	+$304K	0.17%	80
2017 Q2	$7.89M	Sell	115,794 -2,596	-2%	-$170K	0.12%	88
2017 Q1	$7.37M	Buy	+118,390	New	+$6.89M	0.11%	91
2014 Q3	–	Sell	-386,058	Closed	-$28.7M	–	161
2014 Q2	$28.7M	Sell	386,058 -947,836	-71%	-$68.5M	0.35%	54
2014 Q1	$86.5M	Sell	1,333,894 -1,169,954	-47%	-$75.6M	1.09%	39
2013 Q4	$149M	Buy	2,503,848 +122,808	+5%	+$6.67M	1.83%	19
2013 Q3	$124M	Buy	2,381,040 +174,818	+8%	+$8.78M	1.59%	23
2013 Q2	$104M	Buy	+2,206,222	New	+$112M	1.31%	28

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brandes Investment Partners's AZN Position: Q4 2017 in Review

Brandes Investment Partners sold out of AstraZeneca (AZN) in Q4 2017, closing a stake of 120,599 shares — an estimated $8.17M sold.

Brandes Investment Partners first reported a position in AZN in Q2 2013 and held it in 8 quarters. The position peaked at $149M in Q4 2013. 503 funds tracked by Wall St. Rank hold AZN as of Q4 2017.

Brandes Investment Partners reported no remaining AstraZeneca position as of Q4 2017 after selling out during the quarter.
Brandes Investment Partners sold 120,599 AstraZeneca shares in Q4 2017, an estimated $8.17M.
Brandes Investment Partners first reported a position in AstraZeneca in Q2 2013 and held it in 8 quarters.
Brandes Investment Partners's AstraZeneca position peaked at $149M in Q4 2013.
503 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2017.

Based on Brandes Investment Partners's 13F filing for Q4 2017, filed 12 Feb 2018.